Vaccination of mice against Schistosoma bovis with a recombinant fatty acid binding protein from Fasciola hepatica

• Published in: Veterinary parasitology 2000-07, Vol.91 (1), p.33-42
• Main Authors: Abáné, J.López, Oleaga, A, Ramajo, V, Casanueva, P, Arellano, J.L.Perez, Hillyer, G.V, Muro, A
• Format: Article
• Language: English
• Subjects: Animals; Antibodies, Helminth - biosynthesis; Carrier Proteins - immunology; Fasciola hepatica; Fasciola hepatica - immunology; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Helminth Proteins - immunology; Liver - pathology; Mice; Mice, Inbred C57BL; Mouse- Schistosoma bovis; Myelin P2 Protein - immunology; Neoplasm Proteins; Nerve Tissue Proteins; Rabbits; Recombinant protein; Recombinant Proteins - immunology; Schistosoma - immunology; Schistosomiasis - immunology; Schistosomiasis - prevention & control; Schistosomiasis - veterinary; Vaccination - veterinary; Vaccine
• ISSN: 0304-4017; 1873-2550
• DOI: 10.1016/S0304-4017(00)00263-6

Two strains of mice (NMRI and C57/BL) were each immunized with a 15 kDa recombinant Fasciola hepatica fatty acid binding protein (FABP) (Fh15) and challenged percutaneously with Schistosoma bovis cercariae. C57/BL mice immunized with Fh15 had significant reductions in S. bovis worm burden recoveries (72% reductions over controls). When using NMRI mice, Fh15 in Freund’s adjuvant failed to induce significant protection against S. bovis. In C57/BL mice, only antibodies to the IgG2a isotype increased after the second immunization and remained high through 8 weeks of S. bovis infection. This is the first time that a heterologous recombinant molecule from F. hepatica has been used in vaccination against S. bovis, obtaining a significant reduction in the number of worms in C57/BL mice.